A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Post-remission Therapy for High Risk Leukemia or Myelodysplasia

Trial Profile

A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Post-remission Therapy for High Risk Leukemia or Myelodysplasia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2015

At a glance

  • Drugs Romyelocel-L (Primary) ; Filgrastim
  • Indications Neutropenia
  • Focus Adverse reactions
  • Sponsors Cellerant Therapeutics
  • Most Recent Events

    • 01 Sep 2014 Status changed from active, no longer recruiting to completed.
    • 21 Aug 2014 Planned End Date changed to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 21 Aug 2014 Planned primary completion date changed from 1 Mar 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top